Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), or angioplasty, experienced nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox® (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor (GPI), according to data from the ACUITY trial. These findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or enoxaparin. These data were presented today at the European Society of Cardiology (ESC) Congress 2007. The Medicines Company (NASDAQ: MDCO) recently re-acquired rights for Angiox in Europe and currently markets the product as Angiomax® in the United States.
